BridgeBio Pharma's Q2 revenue beats on higher Attruby sales

BridgeBio Pharma

10/08/2026 21:11

Overview
US biopharma firm's Q2 revenue more than doubled yr/yr, beating analyst expectations
Company posted a narrower net loss per share compared to Q2 last yr
BridgeBio closed $1 bln preferred equity financing after quarter-end

Result Drivers
ATTRUBY SALES - Revenue growth was mainly driven by higher U.S. sales of Attruby, led by increased use in treatment-naïve patients
ROYALTY REVENUE - Higher royalty revenue, mainly from BEYONTTRA sales in the EU and Japan, contributed to revenue growth
OPERATING EXPENSES - Operating costs rose due to continued investment in commercialization of Attruby and pre-commercial activities for late-stage pipeline products

Company press release: ID:nGNX1ZSxmV

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$243.68 mln
$218.74 mln (17 Analysts)
Q2 Loss Per Share
 
$0.78
 
Q2 Net Loss
 
$155.89 mln
 
Q2 Operating Income
 
-$107.08 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for BridgeBio Pharma, Inc. is $101.50, about 20.1% above its August 7 closing price of $84.48

Reuters Recommended Reads
Aug 10 - Axsome Therapeutics Q2 revenue rises on AUVELITY  growth
Aug 10 - Cogent Biosciences Q2 net loss widens on higher expenses
Aug 10 - Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)